Skip to main content
Premium Trial:

Request an Annual Quote

Tufts' Clinical and Translational Science Institute Lands $24M from NIH

NEW YORK (GenomeWeb News) – Tufts University Medical Center has received $24 million from the National Institutes of Health to fund its Clinical and Translational Science Institute (CTSI), which hosts core facilities for nucleic acid analysis, a biorepository, training and consultation programs, and other services, Tufts said on Wednesday.

Tufts said its CTSI collaborates with 39 partners, which includes 12 schools and research centers at the university, 10 affiliated hospitals, and five industry partners, among others.

Richard Karas, the chief scientific officer at Tufts Medical Center, said the CTSI, which first received funding in 2008, provides support for clinical trials, lab research, study design, funding for pilot studies, and career development programs.

The CTSI's core center, the Clinical and Translational Research Center, provides a range of services, including specimen processing, storage, and shipping, nucleic acid analysis, immunoassays, and access to bench and freezer space. The CTSI's specimen processing services include DNA and RNA isolation, and its nucleic acid analysis offerings include DNA and RNA analysis, real-time PCR assays, whole genome amplification, and library preparation for next-generation sequencing.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.